



**FRESENIUS  
MEDICAL CARE**

Around

**40**

production sites in around 20 countries

Around

**4,000**

dialysis centers in around 50 countries

Around

**120,000**

employees

More than

**332,000**

patients worldwide

Around

**52M**

dialysis treatments in 2023

## The Company at a Glance

### Financial Figures (in BN €)

**19.45**

Revenue

**0.76 1.74**

Net income<sup>1</sup> excluding special items and PRF<sup>2</sup>

Operating income excluding special items and PRF<sup>2</sup>

### Who We Are

Fresenius Medical Care is the world's leading provider of products and services for people with renal disease. We serve more than 332,000 dialysis patients worldwide and provide products in around 150 countries. Our goal is not only to treat, but also to innovate, to improve the lives of those impacted by kidney disease.

### Vision — Mission — Strategy

Creating a future worth living. For patients. Worldwide. Every day. This vision guides our company to provide people across the renal care continuum with outstanding healthcare and high-quality products. We aim to use our innovative products and services to offer sustainable solutions at a reliable cost around the world. Our commitment to sustainability is an integral part of our strategy.

**Chief Executive Officer and  
Chair of the Management Board**  
Helen Giza



<sup>1</sup> Net income attributable to shareholders of Fresenius Medical Care AG.

<sup>2</sup> For FY 2023, special items include the costs related to the FME25 program, the Humacyte investment remeasurement, the costs associated with the legal form conversion and the effects from legacy portfolio optimization. For FY 2022, special items include the costs related to the FME25 program, the impact of the war in Ukraine, the impact of hyperinflation in Türkiye, the Humacyte investment remeasurement and the net gain related to InterWell Health. Additionally, FY 2022 was adjusted for the U.S. Provider Relief Funding (PRF). For further details please see the reconciliation attached to the press release for the 4th quarter 2023.